News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816
Hidehito Horinouchi/X
Jan 13, 2025, 04:50

Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816

Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by Mark Awad et al. published in Journal of Clinical Oncology:

“CheckMate 816: Neoadjuvant Nivo and Ipi vs chemo in Resectable NSCLC.

Potential long-term clinical benefit.”

“Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer”

Authors: Mark Awad, Patrick Forde, Nicolas Girard, Nan Hu, Mariano Provencio Pulla et al.

Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816

More posts featuring Hidehito Horinouchi.

Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.

He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.

cancer chemotherapy Hidehito Horinouchi ipilimumab Mariano Provencio Pulla Mark Awad Nan Hu Nicolas Girard nivolumab non small cell lung cancer NSCLC OncoDaily Oncology Patrick Forde
Special Coverage
Blog
Apr 13, 2025, 19:03
Tigran Byuzandyan: Delegation from the National Oncology Center of Armenia Explores Collaboration with Heidelberg University Hospital
Blog
Apr 13, 2025, 18:24
Akhil Santhosh: First-Line Adagrasib and Pembrolizumab for Metastatic NSCLC
Blog
Apr 13, 2025, 18:15
12th Annual Cholangiocarcinoma Foundation Conference Comes to a Close
Blog
Apr 13, 2025, 17:50
Noemi Reguart: First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy in SCLC
Blog
Apr 13, 2025, 17:15
Applications are open for the M2ICOS project - European School of Oncology
Stories
Apr 13, 2025, 17:11
From Resident to Survivor: Dr. Jessica Firdman Moore’s cancer journey at Sylvester Comprehensive Cancer Center
Blog
Apr 13, 2025, 17:05
Aruni Ghose: OncoFlow to evaluate AI models across the cancer continuum for clinical adoption
Blog
Apr 13, 2025, 16:53
Heitham Hassoun: All great hospitals are so much more than places to heal
Blog
Apr 13, 2025, 16:28
Rasha Aboelhassan: A fruitful International Society of Clinical Oncology meeting on breast cancer
Blog
Apr 13, 2025, 16:17
The Bulgarian government has adopted an expanded national vaccination programme for HPV - European Cancer Organisation
Blog
Apr 13, 2025, 16:17
Chinmay Jani: SCLC no longer left behind
Blog
Apr 13, 2025, 16:12
Dr. Ira Mellman Joins the Parker Institute as President of Research